Evidence map›Paper›PMID 35330059›Full record

ReviewJournal of clinical medicine2022

PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers.

Diego Teyssonneau, Antoine Thiery-Vuillemin, Charles Dariane, Eric Barret, Jean-Baptiste Beauval, Laurent Brureau, Gilles Créhange, Gaëlle Fiard, Gaëlle Fromont, Mathieu Gauthé and 8 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. PARP inhibitors in prostate cancers, is it time for combinations?Therapeutic advances in medical oncology · 2024
    Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 10 institutions in 1 country.

Diego TeyssonneauDepartment of Medical Oncology, Institut Bergonié, 33000 Bordeaux, France.ORCID 0000-0002-9687-3759
Antoine Thiery-VuilleminDepartment of Medical Oncology, Centre Hospitalier Universitaire Besançon, 25000 Besançon, France.
Charles DarianeDepartment of Urology, Hôpital Européen Georges-Pompidou, AP-HP, Paris University, 75005 Paris, France.ORCID 0000-0002-9573-2938
Eric BarretDepartment of Urology, Institut Mutualiste Montsouris, 75014 Paris, France.
Jean-Baptiste BeauvalDepartment of Urology, La Croix du Sud Hôpital, Quint Fonsegrives, 31000 Toulouse, France.
Laurent BrureauDepartment of Urology, CHU de Pointe-à-Pitre, University of Antilles, 97110 Pointe-à-Pitre, France.
Gilles CréhangeDepartment of Urology, Grenoble Alpes University Hospital, Université Grenoble Alpes, CNRS, Grenoble INP, TIMC-IMAG, 38400 Grenoble, France.
Gaëlle FiardDepartment of Radiation Oncology, Curie Institute, 75005 Paris, France.ORCID 0000-0003-3049-5318
Gaëlle FromontDepartment of Pathology, CHRU Tours, 37000 Tours, France.
Mathieu GauthéDepartment of Nuclear Medicine, Scintep, 38000 Grenoble, France.ORCID 0000-0002-4882-9366
Alain RuffionService d'Urologie Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, 69000 Lyon, France.
Raphaële Renard-PennaDepartment of Radiology, Sorbonne University, AP-HP, Radiology, Pitie-Salpetriere Hospital, 75013 Paris, France.
Romain MathieuDepartment of Urology, University of Rennes, 35000 Rennes, France.
Paul SargosDepartment of Radiotherapy, Institut Bergonié, 33000 Bordeaux, France.
Morgan RouprêtDepartment of Urology, Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital, 75013 Paris, France.
Guillaume PloussardDepartment of Urology, La Croix du Sud Hôpital, Quint Fonsegrives, 31000 Toulouse, France.ORCID 0000-0002-6004-2152
Guilhem RoubaudDepartment of Medical Oncology, Institut Bergonié, 33000 Bordeaux, France.
On Behalf Of The Cc-Afu Cancerology Committee Of The Association Française d'Urologie
Institut Bergonié · FRInstitut polytechnique de Grenoble · FRSorbonne Université · FRAssistance Publique – Hôpitaux de Paris · FRCentre Hospitalier Universitaire de Besançon · FRCentre Hospitalier Universitaire de Tours · FRInserm · FRInstitut Curie · FRInstitute Mutualiste Montsouris · FRUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite recent improvements in survival, metastatic castration-resistant prostate cancers (mCRPCs) remain lethal. Alterations in genes involved in the homologous recombination repair (HRR) pathway are associated with poor prognosis. Poly-ADP-ribose polymerase (PARP) inhibitors (PARPis) have demonstrated anti-tumoral effects by synthetic lethality in patients with mCRPCs harboring HRR gene alterations, in particular

Indexed as

DNA repairhomologous recombination repairPARP inhibitorsprostate cancers

Identifiers

PMID35330059
PMCPMC8952857
OpenAlexW4220745975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.